Kingsview Wealth Management LLC Acquires 15,789 Shares of Becton, Dickinson and Company $BDX

Kingsview Wealth Management LLC boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 448.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,306 shares of the medical instruments supplier’s stock after purchasing an additional 15,789 shares during the period. Kingsview Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $3,613,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in BDX. SOA Wealth Advisors LLC. grew its position in Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 95 shares during the period. Activest Wealth Management grew its position in shares of Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 97 shares during the period. Bell Investment Advisors Inc increased its stake in shares of Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 128 shares during the last quarter. Cornerstone Planning Group LLC raised its holdings in shares of Becton, Dickinson and Company by 463.3% in the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 139 shares during the period. Finally, Accredited Wealth Management LLC lifted its stake in Becton, Dickinson and Company by 77.8% in the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 70 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the sale, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,416 shares of company stock valued at $674,693 in the last three months. 0.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. TD Cowen raised their target price on Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Barclays started coverage on Becton, Dickinson and Company in a report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price objective for the company. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Citigroup reduced their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Finally, Jefferies Financial Group dropped their price target on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and an average price target of $195.46.

Becton, Dickinson and Company Trading Down 1.4%

Shares of BDX opened at $171.80 on Thursday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The stock has a market cap of $48.92 billion, a PE ratio of 28.03, a P/E/G ratio of 12.63 and a beta of 0.24. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The business’s 50-day moving average price is $194.37 and its 200-day moving average price is $191.61.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.15 billion. During the same quarter in the previous year, the company earned $3.43 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its board has initiated a share repurchase program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.